Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.

Abstract

Background: Progress in immunotherapy (IT) has shifted treatment paradigms for multiple malignancies. In March 2019, the combination of nab-paclitaxel and atezolizumab was approved by the US FDA for patients with PD-L1 positive metastatic triple-negative breast cancer based on positive results of the Impassion130 trial. Although numerous studies have examined the prognostic role of PD-L1, the value of this test remains controversial. Results: Here, we presented the cases of three heavily pretreated women with metastatic triple-negative breast cancer who exhibited remarkable responses to combined IT and chemotherapy despite undetectable PD-L1. Conclusion: In our opinion, the current FDA-approved assessment for PD-L1 expression is a reasonable tool for deciding whether to start IT. However, because this approach has many limitations, patients with undetectable PD-L1 expression should still be considered for IT.

• Authors: Alexander Philipovskiy, Karinn Chambers, Ioannis Konstantinidis, Richard McCallum, Javier Corral, Sumit Gaur
• Journal: Immunotherapy (Immunotherapy) Vol. 12 Issue 18 Pg. 1293-1302 (12 2020) ISSN: 1750-7448 [Electronic] England
• PMID: 32988260 (Publication Type: Case Reports, Journal Article)

Chemical References

• 130-nm albumin-bound paclitaxel
• Albumins
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• atezolizumab
• Capecitabine
• Paclitaxel

Topics

• Adult
• Aged
• Albumins (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Capecitabine (therapeutic use)
• Female
• Humans
• Immunotherapy (methods)
• Middle Aged
• Paclitaxel (therapeutic use)
• Treatment Outcome
• Triple Negative Breast Neoplasms (drug therapy, pathology, therapy)